Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × talazoparib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 33 Gynecologic 16 Genitourinary 16 Gastrointestinal 9 Other solid neoplasm 8 Tumor-Agnostic 7 Thoracic 7 Other hematologic neoplasm 7 CNS 4 Sarcoma 3 Myeloid 2 Lymphoid 2 Head & Neck 2 Endocrine 2 Plasma cell 1 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 37 Everolimus 33 Magnetic Resonance Spectroscopy 17 Temozolomide 14 gallium Ga 68 dotatate 13 lanreotide 12 Octreotide 12 Nivolumab 11 Capecitabine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 pembrolizumab 9 Specimen Handling 9 surufatinib 8 cabozantinib 8 Sunitinib 8 pasireotide 7 Positron Emission Tomography Computed Tomography 7 3-Iodobenzylguanidine 7 Lutetium-177 6 Fluorodeoxyglucose F18 6 90Y-octreotide, DOTA-Tyr(3)- 6 amino-acid, glucose, and electrolyte solution 5 Ipilimumab 5 Injections 5 Ga(III)-DOTATOC 5 Etoposide 5 Carboplatin 5 olaparib 4 copper dotatate CU-64 4 avelumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡